rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MIST
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Cut As Cardamyst Launch Concerns Persist

      Milestone Pharmaceuticals is back in focus as updated fair value estimates move from US$5.71 per share to US$4.57, a cut of roughly 20% in the latest pricing work. Recent research points to optimism around Cardamyst’s long term potential along with concern about launch momentum and reimbursement, which helps explain why many price targets now cluster between US$3 and US$5. In the sections that follow, you will see how these shifting targets fit into the broader Milestone Pharmaceuticals story...

      Nov 17Yahoo FinanceMIST
      Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results
      Nov 16BenzingaMIST
      Piper Sandler cuts Milestone Pharmaceuticals stock price target on lower sales
      Nov 16Investing.comMIST
      Milestone Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceMIST
      Milestone Pharmaceuticals Q3 Earnings Call Highlights
      Nov 13Yahoo FinanceMIST
      Why is Milestone Pharmaceuticals stock climbing today?
      Nov 13Investing.comMIST
      Milestone Pharmaceuticals cuts costs 30%, extends cash runway
      Nov 13Investing.comMIST
      Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates
      Nov 13Yahoo FinanceMIST
      Milestone Pharmaceuticals: Q3 Earnings Snapshot
      Nov 13Yahoo FinanceMIST
      Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations
      Oct 23Yahoo FinanceMIST
      Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation
      Oct 9Yahoo FinanceMIST
      Milestone Pharmaceuticals at H.C. Wainwright: launch gains and afib push
      Sep 15Investing.comMIST
      Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead
      Sep 8Investing.comMISTWFC
      H.C. Wainwright reiterates Buy on Milestone stock after China approval
      Sep 4Investing.comMIST
      Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

      Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis

      Sep 3Yahoo FinanceMIST
      Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
      Sep 2Yahoo FinanceMIST
      Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

      MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences. Conference Details Wells Fargo 21st Annual Healthcare Conference Format:Fireside chat and 1x1sPresentation Date:September 8, 2026Time:1:30 pm ETLocation:Bos

      Sep 2Yahoo FinanceMIST
      Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

      Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and WorkMONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) af

      Aug 27Yahoo FinanceMIST
      Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

      Milestone Pharmaceuticals Inc (NASDAQ:MIST) shares gained 3. 9% on Friday after the company announced that the first patient had been enrolled in its Phase 3 ReVeRA-301 study of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR).

      Aug 21Yahoo FinanceMIST
      Milestone Pharmaceuticals stock gains on Phase 3 AFib trial
      Aug 21Investing.comMIST
      Milestone Pharmaceuticals begins phase 3 trial for AFib treatment
      Aug 21Investing.comMIST
      Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

      ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular Rate and Improved Both Symptom Relief and Treatment Satisfaction in AFib-RVR Population MONTREAL and CHARLOTTE, N.C., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of

      Aug 21Yahoo FinanceMIST

      This is the newest page. Registered accounts read further back.